Core Viewpoint - Helix BioPharma Corp. has extended its Research and Exclusive Option Agreement with metaShape Pharma AG for the compound LEUMUNA™ until December 31, 2028, allowing further research and development in metabolic diseases while maintaining a focus on oncology assets [1][4]. Group 1: Agreement Details - The original agreement was established in April 2023 between metaShape and Laevoroc Immunology AG, granting metaShape an exclusive research license and an option for a commercial license for LEUMUNA™ [2]. - The extension of the agreement provides additional time to advance research activities and supports the progression of the program toward clinical-stage development [4]. Group 2: Compound Development - MS 001, the compound under development, is designed as an orally administered co-therapy to GLP-1 receptor agonists, aimed at enhancing adipose tissue reduction and weight loss durability [2]. - Preclinical studies indicated that MS 001 increased levels of inosine and NAD+, which improved mitochondrial function and energy expenditure in adipose tissue, leading to better weight loss outcomes in mice [3]. Group 3: Company Perspectives - The CEO of metaShape expressed excitement about the progress of MS 001 and the developments in the program [5]. - Helix's CEO highlighted the quality of preclinical data around MS 001, particularly its effects on NAD+ biology and fat metabolism, indicating potential benefits across various disease settings [5]. Group 4: Company Backgrounds - MetaShape Pharma, founded in 2023, focuses on developing first-in-class metabolic therapies to address metabolic dysfunction [6]. - Helix BioPharma specializes in oncology, with a pipeline that includes Tumor Defense Breaker™ L-DOS47 and two pre-IND candidates: LEUMUNA™ and GEMCEDA™, aimed at treating hard-to-treat cancers [7].

Core Viewpoint - Helix BioPharma Corp. held its Annual General and Special Meeting on March 26, 2025, where shareholders voted overwhelmingly in favor of all proposed resolutions, indicating strong support for the company's strategic direction and governance [1][2]. Voting Results - A total of 40,294,667 common shares were voted, representing 76.00% of the total issued and outstanding shares [1]. - All four director nominees were re-elected with votes in favor ranging from 99.99% to 99.99% [2]. - The appointment of Clearhouse LLP as the auditor was approved with 99.61% of votes in favor [2]. - The asset transactions with Laevoroc Immunology AG and Laevoroc Chemotherapy AG were approved with 99.61% of votes in favor [3]. - The equity draw-down subscription facility providing access to CA$25,000,000 was approved with 99.61% of votes in favor [4]. - The amendment for share consolidation on a ratio of up to five pre-consolidation shares for one post-consolidation share was approved with 99.98% of votes in favor [5]. - The resolution to change the company's name to "Aconara Pharma Corp." was approved with 99.60% of votes in favor [6]. - The approval of unallocated options and the Equity Compensation Plan for a further three years was approved with 99.60% of votes in favor [7]. Company Overview - Helix BioPharma is focused on developing novel therapies for hard-to-treat cancers, with a pipeline that includes the lead candidate Tumour Defence Breaker™ L-DOS47, which targets CEACAM6-expressing solid tumors [10].

Core Viewpoint - Helix BioPharma Corp. is extending its Annual General and Special Meeting to March 26, 2025, to secure shareholder approval for proposed asset acquisitions and financing arrangements [1][2]. Group 1: Meeting Details - The Annual General and Special Meeting has been rescheduled to March 26, 2025, to allow more time for shareholder approval regarding asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG [1]. - The Ontario Superior Court of Justice approved the application to hold the Meeting by the new date on February 26, 2025 [2]. - Meeting materials, including the Notice of Meeting and Voting Instruction Form, were mailed to shareholders and posted on SEDAR+ on February 24, 2025 [3]. Group 2: Shareholder Participation - Shareholders of record as of January 31, 2025, are eligible to vote at the Meeting and are encouraged to vote in advance [4]. - Proxies must be received by 10 a.m. (EST) on March 24, 2025, to be counted [4]. Group 3: Company Overview - Helix BioPharma Corp. is focused on developing novel therapies for hard-to-treat cancers, with a pipeline that includes a proprietary technology platform targeting CEACAM6-expressing solid tumors [6]. - The lead candidate, Tumour Defence BreakerTM L-DOS47, is an antibody-enzyme conjugate that aims to enhance anti-cancer immunity and has completed Phase Ib studies in non-small cell lung cancer [6][7].